Related Experiment Video
Updated: Oct 16, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
[Insights into a new weapon against cancer: oncolytic viruses]
1CNRS UMR 7151, Université Paris 7, Hôpital Saint-Louis, 1 avenue Claude-Vellefaux, 75475 Paris Cedex 10.
Abstract:
Within the framework of the fight against cancer, oncolytic viruses inducing the specific death of represent tumour cells, a new therapeutic approach. If some viruses such as the reovirus, the parvovirus or the vesicular stomatitis virus are naturally oncotropic, most of viruses assessed for their property to specifically lyse cancer cells are genetically modified. Mostly, these modifications consist in deleting genes which are necessary for replication in normal cells but dispensable in a neoplasic context. Thus, the adenovirus Onyx-015 or the herpes virus G207 are already prone to clinical studies. However, efficiency of these modified viruses is limited by the host's immune system. Moreover, these modified agents derived from their disease-induced wild-type counterparts could potentially evolved in vivo and cause unexpected adverse effects. Therefore, future research will focus on generating safer and tolerated viral tools. In that context, a better knowledge of the biology and the bio-distribution of these viruses is required.
Insights
Oncolytic viruses offer a novel cancer therapy by selectively destroying tumor cells. Research focuses on developing safer, genetically modified viruses with improved efficacy and reduced adverse effects.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Context:
- Oncolytic viruses represent a promising cancer treatment strategy.
- Many oncolytic viruses are genetically modified to enhance tumor cell lysis.
- Current limitations include host immune response and potential for adverse effects.
Purpose:
- To explore the potential of oncolytic viruses as a cancer therapy.
- To discuss the genetic modifications employed in developing oncolytic viruses.
- To highlight the need for safer and more effective viral therapeutic agents.
Summary:
- Oncolytic viruses selectively target and destroy cancer cells, offering a new therapeutic avenue.
- While some viruses are naturally oncotropic, many are genetically engineered for enhanced tumor specificity.
- Adenovirus Onyx-015 and herpes virus G207 are examples in clinical studies.
- Challenges include immune system interference and potential in vivo evolution of modified viruses.
Impact:
- Advances in oncolytic virus therapy could lead to more effective cancer treatments.
- Understanding virus biology and biodistribution is crucial for developing safer viral tools.
- Future research aims to improve the safety and tolerability of oncolytic viral therapies.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:51Mechanisms of Retrovirus-induced Cancers
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...